NCT05881720View on ClinicalTrials.gov

Sacubitril/Valsartan Versus Valsartan in Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

June 18, 2023

Study Completion Date

June 19, 2023

Conditions
Heart Failure
Interventions
DRUG

Sacubitril / Valsartan Oral Tablet

Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.

DRUG

Valsartan 80 mg

group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.

Trial Locations (1)

31527

Tanta University Hospital, Tanta

All Listed Sponsors
collaborator

Tanta University

OTHER

lead

Damanhour University

OTHER

NCT05881720 - Sacubitril/Valsartan Versus Valsartan in Heart Failure | Biotech Hunter | Biotech Hunter